All Opportunities

Confidential Project

Project Viridian

A privately held specialty pharmaceutical company advancing transdermal 505(b)(2) drug programs across CNS, cardiovascular, metabolic, oncology and autoimmune markets.

Industry
Specialty Pharma
Platform
505(b)(2) TDS
5-Yr Revenue
$142.5M
Aggregate NPV
$37.2M
Project Viridian — Investment Teaser Open in New Tab Download

Loading the teaser… if it does not appear, use “Open in New Tab” or “Download” above.

Strictly confidential · Prepared by Intelligentzia Capital Management · Scroll within the frame to navigate pages

Discuss This Project

Explore Project Viridian

Contact our team to receive additional information under NDA.